When was Reprogram Biosciences founded?

Reprogram Biosciences was founded in 2025 and raised its 1st funding round within a year of its incorporation.

Where is Reprogram Biosciences located?

Reprogram Biosciences is headquartered in San Diego, United States.

Who is the current CEO of Reprogram Biosciences?

Rustam Esanov of Reprogram Biosciences. They have also founded 1 company.

How many employees does Reprogram Biosciences have?

As of Jul 31, 2026, the latest employee count at Reprogram Biosciences is 4.

Is Reprogram Biosciences a funded company?

Reprogram Biosciences is a funded company, having raised a total of $6M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 09, 2025.

When was the latest funding round of Reprogram Biosciences?

Reprogram Biosciences' latest funding was a $***** Seed round on Mar 16, 2026, with participation from 3 investors.

Where does Reprogram Biosciences rank among its competitors?

Reprogram Biosciences ranks 1008th amongst 3320 active competitors, of which 1118 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Reprogram Biosciences?

Reprogram Biosciences' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Reprogram Biosciences - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of in vivo cancer cell reprogramming therapies. It transforms cancer cells into immune cells within the patient, using a novel gene cocktail delivered via a lipid nanoparticle system. This approach aims to harness the body's immune system to fight solid tumors, offering a potentially cost-effective treatment. The technology leverages AI/ML-based cell reprogramming and is designed for ready-to-use therapeutic application.

Website: reprogrambio.com
Email ID: *****@reprogrambio.com

Key Metrics

Founded Year

2025

Location

San Diego, United States

Stage

Seed

Total Funding

$6M in 2 rounds

Latest Funding Round

Seed, Mar 16, 2026, $*****

Investors

Narya & 2 more

Ranked

1008^th among 3320 active competitors

Employee Count

4 as on Jul 31, 2026

Similar Companies

BeiGene & 567 more

View Reprogram Biosciences' full profile

Reprogram Biosciences has raised a total funding of $6M over 2 rounds. Its first funding round was on May 09, 2025. Its latest funding round was a Seed round on Mar 16, 2026 for $*****. 3 investors participated in its latest round. Reprogram Biosciences has 3 institutional investors.

Here is the list of recent funding rounds of Reprogram Biosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 16, 2026	7517290	Seed	6492950	5560354	4955634	4579952
May 09, 2025	6512851	Seed	4228962	9148201	1526054	8283427

Access funding benchmarks and valuations. Sign up today!

View details of Reprogram Biosciences's funding rounds and investors

The founders of Reprogram Biosciences are Eziz Kuliyev and Rustam Esanov. Rustam Esanov is the CEO of Reprogram Biosciences.

Here are the details of Reprogram Biosciences' key team members:

Eziz Kuliyev: Co-Founder & COO of Reprogram Biosciences.
Contact Info: 1 email address
Rustam Esanov: Co-Founder & CEO of Reprogram Biosciences.
Contact Info: 1 email address

View details of Reprogram Biosciences's Founder profiles and Board Members

Reprogram Biosciences' employee count trend

Reprogram Biosciences has 4 employees as of Jul 26. Here is Reprogram Biosciences's employee count trend over the years:

Employee count trend for Reprogram Biosciences

Uncover Reprogram Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Reprogram Biosciences include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Reprogram Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1008th	Reprogram Biosciences 2025, San Diego (United States), Seed	Developer of in vivo cancer cell reprogramming therapies	$6M	Narya, 1517 Fund & 1 others	41/100